New Delhi: With key taxation reforms, deregulation efforts, and clearance for pending R&D incentives, 2025 has been an eventful year for the private healthcare sector, creating the right space for entrepreneurial efforts while continuing the upward momentum in public health commitments toward malaria and TB.
Business upgradation moved up with the AI buzz and saw significant developments, with global giants setting up GCCs in India and new startups emerging rapidly, creating a fresh model of accelerated innovation.
“2025 has been the year India’s healthcare sector moved from incremental progress to decisive transformation,” said Ameera Shah, President NATHEALTH adding that, “AI moved from being a tool on the margins to becoming a core capability, across the care continuum.”
According to Shah who also leads one of India’s leading pathology chain, Metropolis, what stands out this year is the sectors increasing investments in automation, data infrastructure and advanced technologies.
“Such advancements are being treated as not as future bets, but as essential foundations for the next phase of healthcare delivery,” she added.
On part of policy, the government rolled out a $12 billion research funds, along with project-based assistance under PRIP for pharma and MedTech, to address funding constraints for innovators.
Officials also unwrapped initiatives for cancer care including, day care centers, duty waivers, followed by the much-awaited GST rationalization, which zeroed out duty on insurance critical drugs, while bringing steep cuts on other sectors.
In 2025, private hospital chains remained aggressive. Manipal’s Rs 6,400-crore Shayadri deal led the marquee moves, Apollo executed major restructuring, and Max Healthcare breached the Rs 1-trillion valuation mark.
Against the broader private sector CAPEX constraints, India’s top hospital chains pressed ahead with multiple greenfield projects, all while keeping their balance sheets robust low net leverage, and stable margins.
Diagnostic chains ventured into deeper tier-2 and tier-3 pockets, cementing demand shifts and exploring untapped opportunities to drive their next phase of growth. However the movement was largely elusive to brownfield expansions.
On the MedTech front, where manufacturers stare at a ’50 per cent tariff wall’ in the US, Himanshu Baid, MD, Poly Medicure Ltd, said, “Despite geopolitical uncertainty and tariff pressures, the industry has shown remarkable stability. Policy measures, including the rollback of select QCOs on chemicals and greater regulatory alignment, have significantly improved the ease of doing business and strengthened confidence in Indian manufacturing.”
For MSMEs, Rajiv Nath, Forum coordinator, AiMeD said, “2025 has laid the groundwork for a more balanced and enabling operating environment and stakeholders saw constructive discussions on regulatory predictability, and the urgent need to reduce import dependence in critical device segments.
Judicial scrutiny of key drug patents held up patient access and affordability concerns over multinational monopolies. Meanwhile, statements from the Prime Minister reflected policymakers’ renewed focus on tackling emerging health challenges such as obesity and antimicrobial resistance (AMR).
Outlook for 2026
The challenge and opportunity for the coming year is clear: to convert technological possibility into measurable health impact. “If 2025 was the year of intent, 2026 must be the year of implementation,” emphasised Ameera Shah, President, NATHEALTH.
In MedTech, strengthening India’s market share—both domestically and globally—will hinge on deeper localisation of critical components, greater investment in high-value R&D, and faster clinical validation to drive adoption, added Himanshu Baid, MD, Poly Medicure Ltd.
To support domestic manufacturing, Rajiv Nath, Forum Coordinator, AiMeD, called for raising tariffs to 10–15% from the current 7.5% and giving preference to ICMED certification over foreign approvals in public procurement.
Looking ahead, according to industry stakeholders 2026 could be the defining year for India’s healthcare transformation. With strategic policy support, deeper localisation of critical technologies, and accelerated R&D and clinical adoption, the sector is poised to set new global benchmarks. Success will not just be measured in financial growth or technological adoption, but in tangible improvements in patient outcomes, accessibility, and affordability—paving the way for India to emerge as a true healthcare innovator on the world stage.
